Details

Project TitleImmunotherapy for Treating Age-Related Macular Degeneration
Track Code2007-161 and 2009-033
Short Description

New approach targeting drusen accumulation for treatment and prevention of age-related macular degeneration.

#ophthalmology #maculardegeneration #therapeutics #smallmolecule

Abstract

Northwestern researchers have identified compounds for the treatment and prevention of drusen, tiny accumulations of extracellular material build-up in the macula. Deposition of drusen in the macula is a key factor in the etiology of Age-related Macular Degeneration (AMD). The researchers use an immunotherapeutic approach using antibodies to target against intracellular proteins that, when they become extracellular, contribute to the formation of drusen. The antigen/antibody response mechanism removes these proteins from the eye, decreasing the formation of drusen. This offers a novel therapeutic treatment for AMD by modulating the formation of drusen.

 
TagsOPHTHALMOLOGY: macular degeneration, THERAPEUTICS: small molecule
 
Posted DateFeb 19, 2013 12:30 PM

Inventor(s)

Arthur Neufeld*
Ai Ling Wang

Applications

  • Therapeutics: AMD
  • Preventative Therapeutics: AMD

Advantages

  • Effective induction of immune response
  • Therapy at various stages of AMD: etiology or existing condition

Publications

IP Status

A patent application has been filed.

Contact Information

Michael Moore, PhD
Invention Manager
(p) (847) 491-4645
(e) michaelmoore@northwestern.edu